Im Erasmushaus,
Bäumleingasse 18,
4051 Basel,
Switzerland
Prinzregentenstr. 64,
81675 München,
Germany
NUCLIDIUM today announced that the first patient has been successfully imaged in a Phase 2 clinical trial evaluating the diagnostic accuracy and safety of the Company’s 61Cu-NU101 radiotracer in patients with metastatic prostate cancer.
Being named to the #Fierce15 recognizes our work to bring the next wave of targeted radiotheranostics to more patients.
NUCLIDIUM today announced announced the closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension, bringing the Series B total raised to CHF 105 million (approx. EUR 115 million).
NUCLIDIUM today announced that U.S. Patent No. 12,527,885 has been granted by the United States Patent and Trademark Office (USPTO). This critical achievement strengthens and extends the scope of the intellectual property portfolio for NUCLIDIUM’s NU101 radiotheranostic program.
NUCLIDIUM was featured by BioCentury in an Emerging Company Profile highlighting the company’s unique copper-based approach in targeted radiotheranostic development
NUCLIDIUM Presents Positive Phase 1 Results of its Novel PET Imaging Agent 61-Cu-NuriPro™ at SNMMI 2025 Annual Meeting
NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States
NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025
NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
NUCLIDIUM Presents Positive Phase 1 Results of its Novel PET Imaging Agent 61-Cu-NuriPro™ at SNMMI 2025 Annual Meeting
NUCLIDIUM Appoints Tony Rosenberg as Chairman of the Board
NUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer
Collaboration Partners LinaThera, NUCLIDIUM, Medical Valley Center Forchheim, Klinikum Bayreuth und Erlangen University Hospital Receive Funding from Oberfrankenstiftung for the Production and Clinical Development of Radionuclide Therapies
NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM and PharmaLogic Form Strategic Partnership for Sustainable Development of Novel Copper-based Theranostics to Diagnose and Treat Solid Tumours
NUCLIDIUM and University Hospital Basel Receive NETRF Investigator Award to Initiate Phase 1 Trial with Novel Copper-based Radiotheranostic Program TraceNET in Neuroendocrine Tumours
Nuclidium has won a second Innosuisse Grant of €800.000 to improve treatment of carcinomas via precision imaging of the tumour microenvironment with a novel Copper-61-based PET tracer.
The European Innovation Council (EIC) has awarded Nuclidium with its Accelerator grant of €2,5 million to develop novel, broadly available Copper-based PET tracers for the diagnosis of a broad range of cancer indications.
Innosuisse has awarded Nuclidium with a €1 million grant to further advance its development of a proprietary platform of novel PET tracers based on Copper-61.
NUCLIDIUM today announced that the first patient has been successfully imaged in a Phase 2 clinical trial evaluating the diagnostic accuracy and safety of the Company’s 61Cu-NU101 radiotracer in patients with metastatic prostate cancer.
Being named to the #Fierce15 recognizes our work to bring the next wave of targeted radiotheranostics to more patients.
NUCLIDIUM today announced announced the closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension, bringing the Series B total raised to CHF 105 million (approx. EUR 115 million).
NUCLIDIUM today announced that U.S. Patent No. 12,527,885 has been granted by the United States Patent and Trademark Office (USPTO). This critical achievement strengthens and extends the scope of the intellectual property portfolio for NUCLIDIUM’s NU101 radiotheranostic program.
NUCLIDIUM was featured by BioCentury in an Emerging Company Profile highlighting the company’s unique copper-based approach in targeted radiotheranostic development
NUCLIDIUM Presents Positive Phase 1 Results of its Novel PET Imaging Agent 61-Cu-NuriPro™ at SNMMI 2025 Annual Meeting
NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States
NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025
NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
NUCLIDIUM Presents Positive Phase 1 Results of its Novel PET Imaging Agent 61-Cu-NuriPro™ at SNMMI 2025 Annual Meeting
NUCLIDIUM Appoints Tony Rosenberg as Chairman of the Board
NUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer
Collaboration Partners LinaThera, NUCLIDIUM, Medical Valley Center Forchheim, Klinikum Bayreuth und Erlangen University Hospital Receive Funding from Oberfrankenstiftung for the Production and Clinical Development of Radionuclide Therapies
NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM and PharmaLogic Form Strategic Partnership for Sustainable Development of Novel Copper-based Theranostics to Diagnose and Treat Solid Tumours
NUCLIDIUM and University Hospital Basel Receive NETRF Investigator Award to Initiate Phase 1 Trial with Novel Copper-based Radiotheranostic Program TraceNET in Neuroendocrine Tumours
Nuclidium has won a second Innosuisse Grant of €800.000 to improve treatment of carcinomas via precision imaging of the tumour microenvironment with a novel Copper-61-based PET tracer.
The European Innovation Council (EIC) has awarded Nuclidium with its Accelerator grant of €2,5 million to develop novel, broadly available Copper-based PET tracers for the diagnosis of a broad range of cancer indications.
Innosuisse has awarded Nuclidium with a €1 million grant to further advance its development of a proprietary platform of novel PET tracers based on Copper-61.
NUCLIDIUM today announced that the first patient has been successfully imaged in a Phase 2 clinical trial evaluating the diagnostic accuracy and safety of the Company’s 61Cu-NU101 radiotracer in patients with metastatic prostate cancer.
Being named to the #Fierce15 recognizes our work to bring the next wave of targeted radiotheranostics to more patients.
NUCLIDIUM today announced announced the closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension, bringing the Series B total raised to CHF 105 million (approx. EUR 115 million).
NUCLIDIUM today announced that U.S. Patent No. 12,527,885 has been granted by the United States Patent and Trademark Office (USPTO). This critical achievement strengthens and extends the scope of the intellectual property portfolio for NUCLIDIUM’s NU101 radiotheranostic program.
NUCLIDIUM was featured by BioCentury in an Emerging Company Profile highlighting the company’s unique copper-based approach in targeted radiotheranostic development
NUCLIDIUM Presents Positive Phase 1 Results of its Novel PET Imaging Agent 61-Cu-NuriPro™ at SNMMI 2025 Annual Meeting
NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States
NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025
NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
NUCLIDIUM Presents Positive Phase 1 Results of its Novel PET Imaging Agent 61-Cu-NuriPro™ at SNMMI 2025 Annual Meeting
NUCLIDIUM Appoints Tony Rosenberg as Chairman of the Board
NUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer
Collaboration Partners LinaThera, NUCLIDIUM, Medical Valley Center Forchheim, Klinikum Bayreuth und Erlangen University Hospital Receive Funding from Oberfrankenstiftung for the Production and Clinical Development of Radionuclide Therapies
NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress
NUCLIDIUM and PharmaLogic Form Strategic Partnership for Sustainable Development of Novel Copper-based Theranostics to Diagnose and Treat Solid Tumours
NUCLIDIUM and University Hospital Basel Receive NETRF Investigator Award to Initiate Phase 1 Trial with Novel Copper-based Radiotheranostic Program TraceNET in Neuroendocrine Tumours
Nuclidium has won a second Innosuisse Grant of €800.000 to improve treatment of carcinomas via precision imaging of the tumour microenvironment with a novel Copper-61-based PET tracer.
The European Innovation Council (EIC) has awarded Nuclidium with its Accelerator grant of €2,5 million to develop novel, broadly available Copper-based PET tracers for the diagnosis of a broad range of cancer indications.
Innosuisse has awarded Nuclidium with a €1 million grant to further advance its development of a proprietary platform of novel PET tracers based on Copper-61.
Our CEO Leila Jaafar will present the company and our unique copper-based approach at the upcoming conferences. Meet us there!